Governance IXICO plc

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:22 09/06/2026 pm IST			5-day change	1st Jan Change
8.650 ^GBX	0.00%		0.00%	-26.38%

08/06	Ixico plc Announces Appointments on Scientific Advisory Board	CI
08/06	Ixico Has Enters into A Research Collaboration with the Paris Brain Institute	CI

Executive Committee: IXICO plc

Manager

Positions heldSince

Bram Goorden

53 year

Chief Executive Officer

19/08/2024

Grant Nash

50 year

Chief Operating Officer	21/08/2019
Director of Finance/CFO	21/08/2019
Corporate Secretary	31/05/2019

Robin Wolz

Chief Tech/Sci/R&D Officer

01/01/2021

Mark Austin

Chief Tech/Sci/R&D Officer

01/06/2025

Hannah Esfahanian

Human Resources Officer

01/01/2022

Anna-Maria Moseley

General Counsel

01/01/2020

Composition of the Board of Directors: IXICO plc

Director

CommitteesSince

Mark Warne

51 year

Chairman
Independent Dir/Board Member	16/09/2016

Dipti Amin

62 year

Compensation Committee
Audit Committee	05/10/2023
Compensation Committee Chair	05/10/2023

Katherine Rogers

60 year

Compensation Committee
Audit Committee Chair	30/04/2022

Grant Nash

50 year

Director/Board Member

21/08/2019

Bram Goorden

53 year

Director/Board Member

19/08/2024

Latest Appointments: IXICO plc

08/06	Ixico plc Announces Appointments on Scientific Advisory Board	CI
05/02	Ixico Names Chief Commercial Officer	MT
05/02	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
01/12	IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025	CI
17/25/17	EARNINGS AND TRADING: HEIT changes tack and backs Foresight cash bid	AN
10/24/10	EARNINGS AND TRADING: Dianomi trading in line; Solid State profit dips	AN
05/24/05	Ixico names Bram Goorden as next chief executive officer	AN

More news

Former Officers and Directors: IXICO plc

Insider

Positions held

SinceUntil

Giulio Cerroni

Director/Board Member	06/02/2017	16/08/2024
Chief Executive Officer	06/02/2017	19/08/2024

Charles Spicer

Director/Board Member	14/10/2013	16/09/2016
Chairman	16/09/2016	01/01/2024
Corporate Officer/Principal	14/10/2013	29/01/2016

John Bradshaw

Director/Board Member	14/10/2013	30/04/2022
Independent Dir/Board Member	14/10/2013	30/04/2022

Lammert Albers

Corporate Officer/Principal

28/10/2019

01/01/2022

John Hall

Corporate Officer/Principal

15/10/2013

01/03/2020

Conor Wolfson

Comptroller/Controller/Auditor	-	31/05/2019
Director of Finance/CFO	11/12/2018	29/04/2019

Susan Lowther

Director/Board Member	01/10/2014	11/12/2018
Director of Finance/CFO	01/10/2014	11/12/2018
Corporate Secretary	-	11/12/2018

Derek Lionel Glendon Hill

Director/Board Member	15/10/2013	22/01/2018
Chief Executive Officer	28/11/1995	06/02/2017
Founder	28/11/1995	22/01/2018
Corporate Officer/Principal	22/05/2017	22/01/2018

Kate McLeish

Chief Tech/Sci/R&D Officer

01/01/2005

01/07/2017

Janet Munro

Corporate Officer/Principal

01/12/2015

01/06/2017

David Brister

Director/Board Member	01/12/2015	16/09/2016
Independent Dir/Board Member	01/12/2015	-

Andrew Richards

Chairman	01/01/2009	16/09/2016
Independent Dir/Board Member	01/01/2009	16/09/2016

Kenneth M. Tubman

Corporate Officer/Principal

01/12/2015

Krish Ramakrisnan

Sales & Marketing

31/03/2014

Jane Whitrow

Chief Operating Officer	15/10/2013	-
Investor Relations Contact	15/10/2013	-
Corporate Secretary	15/10/2013	-

Timothy Sharpington

Director/Board Member	15/10/2013	-
Independent Dir/Board Member	15/10/2013	-

Michelle Lax

Chief Tech/Sci/R&D Officer

01/01/2012

Maina Bhaman

Director/Board Member

01/01/2010

Romina Oxborough

Chief Operating Officer

Age distribution of managers

Parity Men Women

Male	7
Female	4

Of which Executive Committee

Male	4
Female	2

Of which Directors

Male	4
Female	1

IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.

Employees

Sector

Biotechnology & Medical Research

More about the company